Printer Friendly
The Free Library
14,574,814 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Q4 2005 GlaxoSmithKline Earnings Conference Call - Research and Markets Offers a Brief of 'GlaxoSmithKline' Conference Call.


DUBLIN, Ireland -- The GlaxoSmithKline (NYSE NYSE

See: New York Stock Exchange
:GSK GSK GlaxoSmithKline plc (pharmaceutical company)
GSK Glycogen Synthase Kinase
GSK Gruppentraining Sozialer Kompetenzen (Germany)
GSK Greenland Shark (FAO fish species code) 
) Corporate Conference Call took place on 8-Feb-06 2:00pm UKT UKT Quakertown, Pennsylvania (Airport Code)
UKT You Know That
.

Management announced 2005 EPS (Encapsulated PostScript) A PostScript file format used to transfer a graphic image between applications and platforms. EPS files contain PostScript code as well as an optional preview image in TIFF, WMF, PICT or EPSI, the latter being an ASCII-only format.  growth of 18% and 4Q05 EPS growth of 33%. 2006 EPS growth guidance is around 10% at constant exchange rate.

More information on this Conference Call can be obtained from Research and Markets at http://www.researchandmarkets.com/transcripts/79557

This document provides a non-biased summary of the conference call detailing the key points and the full Q&A session.
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Feb 8, 2006
Words:80
Previous Article:ACT Teleconferencing and Applied Global Technologies(R) Announce Strategic Partnership to Offer IP Video Conferencing Products and Services.
Next Article:Q4 2005 InterActiveCorp Earnings Conference Call - Research and Markets Offers a Brief of 'InterActiveCorp' Conference Call.
Topics:



Related Articles
New GlaxoSmithKline Q2 2005 Newsletter Includes How the Company Experiences Increased Profitability and Revenue.
Shionogi & Co Ltd, a Company Report from 2000-2005 Covering Deals, Partnering Companies and Financial Information.
Adolor and GlaxoSmithKline Report Positive Top-Line Results in Phase 3 Study 314 of Entereg(R) (Alvimopan) in Postoperative Ileus.
Research and Markets: Get an Overview of the Deals Made By GlaxoSmithKline Over a Five Year Period.
Research and Markets: Glaxosmithkline Has Continued to Increase Sales Despite Revenue Falling in Some Product Categories.
Myogen to Announce 2006 Second Quarter Results on August 7, 2006.
Flamel Technologies Announces Second Quarter Results; Reduced Expense Levels; Further Financial Investment from GlaxoSmithKline.
FDA Issues Approvable Letter for Entereg(R) (alvimopan) for POI.
GlaxoSmithKline and XenoPort Announce Agreement on Late-Stage Compound for RLS and Neuropathic Pain.
Vertex Pharmaceuticals Announces the Date of its First Quarter 2007 Financial Results Conference Call and Webcast.

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles